Evelo Biosciences
About Evelo Biosciences
The gut is a central organ of the immune system which controls immunity and inflammation through its interactions with microbes in the small intestine
We are developing a new class of oral biologic therapies that engage immune cells in the small intestine to transmit effects throughout the body
Modulation of this “gut-body network" has therapeutic potential in many major diseases
For general inquiries contact: info@evelobio.com
For media inquiries contact: media@evelobio.com
For investor inquiries contact: ir@evelobio.com
NASDAQ EVLO
122 articles about Evelo Biosciences
-
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
2/7/2022
Evelo Biosciences, Inc. today announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis.
-
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
1/17/2022
Evelo Biosciences, Inc. today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis.
-
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
1/4/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, announced its strategic priorities and upcoming catalysts for 2022.
-
Evelo Biosciences Added to Nasdaq Biotechnology Index
12/14/2021
Evelo Biosciences, Inc. today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.
-
Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
11/9/2021
Evelo Biosciences, Inc. today announced that management will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th , 2021 at 6:20 a.m. ET (11:20 a.m. GMT).
-
Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
10/28/2021
Evelo Biosciences, Inc. today reported financial results and business highlights for the third quarter 2021.
-
Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
10/21/2021
Evelo Biosciences, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights.
-
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
10/13/2021
Evelo Biosciences, Inc. today presented preclinical data for EDP1867, a non-live pharmaceutical preparation of a single strain of Veillonella parvula, at ECTRIMS 2021, October 13-15, 2021.
-
It was a busy week for clinical trial news. Here’s a look.
-
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
9/27/2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis.
-
Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
9/20/2021
Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monday, September 27th, 2021 at 1:20 p.m. ET.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines
9/9/2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new type of orally delivered medicines, announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria.
-
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
9/7/2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.
-
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
7/29/2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, reported financial results and business highlights for the second quarter 2021.
-
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
7/22/2021
Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights.
-
Evelo Biosciences Announces Grant of Inducement Award - July 14, 2021
7/14/2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on July 12, 2021, Ayse Kocak commenced her services as Evelo’s Head of International & Special Projects.
-
Evelo Biosciences Announces Grant of Inducement Award
6/16/2021
Evelo Biosciences, Inc. announced that on June 14, 2021, Mark Plinio commenced his services as Evelo’s Chief Commercial Officer.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.